Oncology

Genomic Approaches To The Study Of Gliomas

We welcome you to a selection of talks from "Diagnosis and Therapeutic Discovery in Neuro-Oncology." We are honored to present to you a unique group of basic and clinical oncologists, who presented their current data in both clinical and basic research areas. The live program addressed cutting edge research in oncology. Thank you for participating in this self-study course.

Dr. Nelson describes gene expression experiments that provide a powerful basis for exploring molecular phenotypes that have not been previously identified based on morphology or limited genetic testing. Gene expression analysis of primary glioblastoma tumor biopsies reveals substantial new information about cancer cells.

Genomic Profiling In Pediatric Glioma

We welcome you to a selection of talks from "Diagnosis and Therapeutic Discovery in Neuro-Oncology." We are honored to present to you a unique group of basic and clinical oncologists, who presented their current data in both clinical and basic research areas. The live program addressed cutting edge research in oncology. Thank you for participating in this self-study course.

Dr. Wong describes how DNA microarrays can be applied to interrogate the alteration of gene expression profiles and allelic imbalance in pediatric glioma. Dr. Wong presents expression profiling results from a study of 21 cases of juvenile pilocytic astrocytoma.

Correlating Genomic Profiles With Clinical Variables In Pediatric Ependymoma

We welcome you to a selection of talks from "Diagnosis and Therapeutic Discovery in Neuro-Oncology." We are honored to present to you a unique group of basic and clinical oncologists, who presented their current data in both clinical and basic research areas. The live program addressed cutting edge research in oncology. Thank you for participating in this self-study course.

Dr. Johnson's microarray gene expression profiling results demonstrate that pediatric intracranial ependymomas can be classified on the molecular level based on their histologic grade. Dr. Johnson presents molecular evidence to support the hypothesis that histologic grade correlates with clinical outcome.

HER2-Targeted Cell Therapy For Medulloblastoma

We welcome you to a selection of talks from "Diagnosis and Therapeutic Discovery in Neuro-Oncology." We are honored to present to you a unique group of basic and clinical oncologists, who presented their current data in both clinical and basic research areas. The live program addressed cutting edge research in oncology. Thank you for participating in this self-study course.

Dr. Gottschalk describes how to genetically modify T cells to express chimeric antigen receptors specific for HER2 (HER2-T cells). The goal of this research is to employ HER2-T cells as an immunotherapeutic approach for HER2 positive medulloblastoma.

Novel Therapies In Pediatric CNS Tumors

We welcome you to a selection of talks from "Diagnosis and Therapeutic Discovery in Neuro-Oncology." We are honored to present to you a unique group of basic and clinical oncologists, who presented their current data in both clinical and basic research areas. The live program addressed cutting edge research in oncology. Thank you for participating in this self-study course.

Dr. Su discusses two therapeutic approaches for pediatric CNS tumors: histone deacetylase (HDAC) inhibitors and poly(ADP-ribose) polymerase (PARP) inhibitors.

Mouse Models Of Medulloblastoma

We welcome you to a selection of talks from "Diagnosis and Therapeutic Discovery in Neuro-Oncology." We are honored to present to you a unique group of basic and clinical oncologists, who presented their current data in both clinical and basic research areas. The live program addressed cutting edge research in oncology. Thank you for participating in this self-study course.

Dr. Rao describes how to employ the RCAS/tv-a system as a model for medulloblastoma. This system uses a retroviral vector (RCAS) and a transgenic mouse line (Ntv-a), and produces medulloblastoma in mice that are similar to tumors found in humans.

Discovering Signaling Targets & Identifying Biomarkers

We welcome you to a selection of talks from the live symposium titled, From Discovery to Application: Biomarkers, Diagnostics, and Molecular Therapeutics in Cancer. We are honored to present to you many world leaders in science. The program addresses dramatic advances in translational oncology, including discussions of target discovery, target validation, and drug development. Thank you for participating in this self-study course.

 

Dr. Pandey’s talk focuses on a strategy called SILAC (stable isotope labeling with amino acids in cell cultures), a technique that utilizes mass spectrometry to quantify protein expression levels in cell culture. One can compare cancer and normal cell lines using the SILAC method to characterize the signaling pathways that are altered in cancer cells.

Pharmacogenomics At The Bedside

We welcome you to a selection of talks from the live symposium titled, From Discovery to Application: Biomarkers, Diagnostics, and Molecular Therapeutics in Cancer. We are honored to present to you many world leaders in science. The program addresses dramatic advances in translational oncology, including discussions of target discovery, target validation, and drug development. Thank you for participating in this self-study course.

 

Dr. Ross describes pharmacogenomics techniques (immunohistochemistry, fluorescence in situ hybridization, mRNA profiling, etc.) that can play a role in predicting a patient's response (sensitivity vs. resistance) to therapeutic drugs. Dr. Ross's discussion is in the context of HER-2 positive breast cancer.

Cancer Genome Project

We welcome you to a selection of talks from the live symposium titled, From Discovery to Application: Biomarkers, Diagnostics, and Molecular Therapeutics in Cancer. We are honored to present to you many world leaders in science. The program addresses dramatic advances in translational oncology, including discussions of target discovery, target validation, and drug development. Thank you for participating in this self-study course.

 

Dr. Golub describes how researchers can create a ‘gene expression signature’ in response to RNAi or small molecule exposure. Numerous signatures are compiled into a ‘signature database’, allowing researchers to characterize the gene expression signatures of disease states and the change in gene expression in response to drugs/therapies. These data are being used to generate the ‘Connectivity Map’.

Shp2 and Its Binding Proteins in Cancer Biology

We welcome you to a selection of talks from the live symposium titled, From Discovery to Application: Biomarkers, Diagnostics, and Molecular Therapeutics in Cancer. We are honored to present to you many world leaders in science. The program addresses dramatic advances in translational oncology, including discussions of target discovery, target validation, and drug development. Thank you for participating in this self-study course.

 

Dr. Neel reviews the normal biological role of Shp2 (a tyrosine phosphatase), as well as the Shp2 mutants that cause Noonan Syndrome and some cancers. Dr. Neel describes how some tumors arise not from Shp2 mutations, but from the over-expression of Shp2 binding proteins, such as the Gab2 protein.

EGFR Mutants: Biology & Therapeutic Opportunities

We welcome you to a selection of talks from the live symposium titled, From Discovery to Application: Biomarkers, Diagnostics, and Molecular Therapeutics in Cancer. We are honored to present to you many world leaders in science. The program addresses dramatic advances in translational oncology, including discussions of target discovery, target validation, and drug development. Thank you for participating in this self-study course.

 

Dr. Haber addresses the goal of predicting a patient’s response to cancer therapies based on the mutations found in their tumors/cancer cells, with a focus on EGFR (epidermal growth factor receptor) mutations that lead to lung cancer. Dr. Haber also discusses identification of mutations that lead to drug resistance.

Tumor & Blood-based Biomarkers for VEGF Pathway Inhibitors

We welcome you to a selection of talks from the live symposium titled, From Discovery to Application: Biomarkers, Diagnostics, and Molecular Therapeutics in Cancer. We are honored to present to you many world leaders in science. The program addresses dramatic advances in translational oncology, including discussions of target discovery, target validation, and drug development. Thank you for participating in this self-study course.

 

The focus of Dr. Heymach’s presentation is on identifying biomarkers that reflect the biological effect of VEGF (vascular endothelial growth factor) inhibitors. VEGF represents a target for antiangiogenic therapies, and his data suggest that tumor- and blood-based markers may be useful for predicting a patient’s response to VEGF inhibitors.

Cancer Drug Development & Somatic Genetic Alterations

We welcome you to a selection of talks from the live symposium titled, From Discovery to Application: Biomarkers, Diagnostics, and Molecular Therapeutics in Cancer. We are honored to present to you many world leaders in science. The program addresses dramatic advances in translational oncology, including discussions of target discovery, target validation, and drug development. Thank you for participating in this self-study course.

 

Dr. Sellers describes how to identify somatic genetic alterations that contribute to cancer, including the use of high-density SNP (single nucleotide polymorphism) arrays. Primary tumors and cell lines are analyzed to measure gene amplification, and researchers look for differential sensitivity to drugs based on the patient’s genetics. A goal is to improve patient selection for clinical trials.